3-Guanidinopropionic Acid
(Synonyms: 胍基丙酸; RGX-202; 3-Guanidinopropionic acid) 目录号 : GC13992A creatine analog
Cas No.:353-09-3
Sample solution is provided at 25 µL, 10mM.
3-Guanidinopropionic Acid is an AMP-activated protein kinase (AMPK) stimulator and PPARγ coactivator 1α (PGC-1α) activator.
AMP-activated protein kinase is an enzyme involved in cellular energy homeostasis. AMPK activation has been involved in stimulation of hepatic fatty acid oxidation, ketogenesis, skeletal muscle fatty acid oxidation and glucose uptake, inhibition of cholesterol synthesis, lipogenesis, and triglyceride synthesis, inhibition of adipocyte lipolysis and lipogenesis, and modulation of insulin secretion by pancreatic beta-cells [1]. PGC-1α is a transcriptional coactivator involved in regulating the genes implicated in energy metabolism and mitochondrial biogenesis, such as the the expression of AMPK, genes for oxidative phosphorylation, electron transport chain, and mitochondrial biogenesis, increasing oxidative muscle fibers, numbers of mitochondria, and motor performance [2].
3-Guanidinopropionic acid improved insulin sensitivity and promoted weight loss selectively from adipose tissue in animal models of non-insulin-dependent diabetes mellitus (NIDDM). 3-Guanidinopropionic acid was a substrate for both the creatine transporter and creatine kinase [3]. In KKAy mice with noninsulin-dependent diabetes, 3-guanidinopropionic acid decreased the plasma glucose level. In insulin-resistant rhesus monkeys, 3-guanidinopropionic acid increased the disappearance of i.v. glucose [4].
References:
[1] Winder W W, Hardie D G. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes[J]. American Journal of Physiology-Endocrinology And Metabolism, 1999, 277(1): E1-E10.
[2] Chaturvedi, R. K.,Adhihetty, P.,Shukla, S., et al. Impaired PGC-1α function in muscle in Huntington’s disease. Human Molecular Genetics 18(16), 3048-3065 (2009).
[3] Larsen S D, Connell M A, Cudahy M M, et al. Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent[J]. Journal of medicinal chemistry, 2001, 44(8): 1217-1230.
[4] Meglasson M D, Wilson J M, Yu J H, et al. Antihyperglycemic action of guanidinoalkanoic acids: 3-guanidinopropionic acid ameliorates hyperglycemia in diabetic KKAy and C57BL6Job/ob mice and increases glucose disappearance in rhesus monkeys[J]. Journal of Pharmacology and Experimental Therapeutics, 1993, 266(3): 1454-1462.
Cas No. | 353-09-3 | SDF | |
别名 | 胍基丙酸; RGX-202; 3-Guanidinopropionic acid | ||
化学名 | N-(aminoiminomethyl)-β-alanine | ||
Canonical SMILES | NC(NCCC(O)=O)=N | ||
分子式 | C4H9N3O2 | 分子量 | 131.1 |
溶解度 | ≥ 13.1mg/mL in Water | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 7.6278 mL | 38.1388 mL | 76.2777 mL |
5 mM | 1.5256 mL | 7.6278 mL | 15.2555 mL |
10 mM | 0.7628 mL | 3.8139 mL | 7.6278 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet